AS Rathore
John Wiley & Sons
e druk, 2009
9780470282335
Quality by Design for Biopharmaceuticals – Principles and Case Studies
Principles and Case Studies
Specificaties
Gebonden, 312 blz.
|
Engels
John Wiley & Sons |
e druk, 2009
ISBN13: 9780470282335
Rubricering
Onderdeel van serie
Wiley Series in Biotechnology and Bioengineering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
This is the first book that explains the underlying concepts of Quality by Design (QbD) and the practical aspects of implementing QbD in biopharmaceutical manufacturing. A systematic approach leads the reader through a process, outlining the understanding of the critical quality attributes of the molecule, the development of the design space to meet the quality attributes, filing of the QbD information in regulatory documents, risk management, and the application of QbD. Complete with real–world case studies, this is a core reference for scientists in the biopharmaceutical industry, regulatory agencies, and students.
Specificaties
Inhoudsopgave
Foreword xiii
<p>Preface xv</p>
<p>Preface to the Wiley Series on Biotechnology and Related Topics xvii</p>
<p>Contributors xix</p>
<p>1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1<br /> Rohin Mhatre and Anurag S. Rathore</p>
<p>1.1 Introduction 1</p>
<p>1.2 Critical Quality Attributes 2</p>
<p>1.3 An Overview of Design Space 3</p>
<p>1.4 Raw Materials and their Impact on QbD 4</p>
<p>1.5 Process Analytical Technology 4</p>
<p>1.6 The Utility of Design Space and QbD 5</p>
<p>1.7 Conclusions 7</p>
<p>2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9<br /> Steven Kozlowski and Patrick Swann</p>
<p>2.1 Introduction 9</p>
<p>2.2 Quality by Design 10</p>
<p>2.3 Relevant Product Attributes 11</p>
<p>2.4 Manufacturing Process 14</p>
<p>2.5 Developing a Design Space 18</p>
<p>2.6 Uncertainty and Complexity 22</p>
<p>2.7 Future Horizons 23</p>
<p>2.8 QbD Submission Thoughts 25</p>
<p>2.9 Implementation Plans 26</p>
<p>2.10 Summary 27</p>
<p>3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31<br /> David L. Narum</p>
<p>3.1 Introduction 31</p>
<p>3.2 The Malaria Genome and Proteome 34</p>
<p>3.3 Expression of Two Malaria Antigens in P. pastoris 34</p>
<p>3.4 Summary 46</p>
<p>4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53<br /> Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman</p>
<p>4.1 Introduction 53</p>
<p>4.2 Examples of Criticality Determination 60</p>
<p>4.3 Conclusion 81</p>
<p>5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85<br /> Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore</p>
<p>5.1 Introduction 85</p>
<p>5.2 Approach Toward Process Characterization 87</p>
<p>5.3 Risk Analysis 88</p>
<p>5.4 Small–Scale Model Development and Qualification 89</p>
<p>5.5 Design of Experiment Studies 94</p>
<p>5.6 Worst Case Studies 96</p>
<p>5.7 Definition of Design Space 99</p>
<p>5.8 Definition of Validation Acceptance Limits 103</p>
<p>5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106</p>
<p>6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111<br /> Peter K. Watler and John Rozembersky</p>
<p>6.1 Introduction 111</p>
<p>6.2 Applications of TFF in Biotechnology 113</p>
<p>6.3 Tangential Flow Filtration Operating Principles 113</p>
<p>6.4 TFF Design Objectives 115</p>
<p>6.5 Membrane Selection 115</p>
<p>6.6 TFF Operating Parameter Design 118</p>
<p>6.7 TFF Diafiltration Operating Mode Design 122</p>
<p>6.8 Summary 125</p>
<p>7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127<br /> Douglas J. Cecchini</p>
<p>7.1 Introduction 127</p>
<p>7.2 Establishing Design Space for Purification Processes during Process Development 128</p>
<p>7.3 Applications of Design Space 131</p>
<p>7.4 Cell Harvest and Product Capture Steps 131</p>
<p>7.5 Protein A Capture Column 136</p>
<p>7.6 Hydrophobic Interaction Chromatography 137</p>
<p>7.7 Anion Exchange Chromatography 138</p>
<p>7.8 Summary 141</p>
<p>8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143<br /> Gail Sofer and Jeffrey Carter</p>
<p>8.1 Introduction 143</p>
<p>8.2 Current and Future Approaches to Virus Clearance Characterization 143</p>
<p>8.3 Benefits of Applying Design Space Principles to Virus Clearance 144</p>
<p>8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145</p>
<p>8.5 Developing a Virus Clearance Design Space 148</p>
<p>8.6 Staying in the Design Space 156</p>
<p>8.7 Conclusion 157</p>
<p>9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161<br /> Kingman Ng and Natarajan Rajagopalan</p>
<p>9.1 Introduction 161</p>
<p>9.2 Quality by Design (QbD) Approach 162</p>
<p>9.3 Target Product Profile (TPP) 163</p>
<p>9.4 Molecular Degradation Characterization 164</p>
<p>9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166</p>
<p>9.6 Preformulation Characterization 167</p>
<p>9.7 Initial Formulation Risk Assessments 168</p>
<p>9.8 Formulation Optimization and Design Space 169</p>
<p>9.9 Selection of Solution Formulation Composition 171</p>
<p>9.10 Summary 173</p>
<p>10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175<br /> Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee</p>
<p>10.1 Introduction: QbD in Biologics Product Development 175</p>
<p>10.2 Risk Assessment Process 177</p>
<p>10.3 Examples 178</p>
<p>10.4 Conclusions 191</p>
<p>11 QbD FOR RAW MATERIALS 193<br /> Maureen Lanan</p>
<p>11.1 Introduction 193</p>
<p>11.2 Background 194</p>
<p>11.3 Current Practice for Raw Materials 195</p>
<p>11.4 QbD in Development 195</p>
<p>11.5 QbD in manufacturing 196</p>
<p>11.6 QbD for organizations 197</p>
<p>11.7 Tests Available 197</p>
<p>11.8 Conclusions and Future Prospects 207</p>
<p>12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211<br /> Michael Molony and Cenk Undey</p>
<p>12.1 Introduction 211</p>
<p>12.2 Cell Culture and Fermentation PAT Tools 214</p>
<p>12.3 Purification PAT Tools 223</p>
<p>12.4 Formulation PAT Tools 228</p>
<p>12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230</p>
<p>12.6 Chemometrics and Advanced Process Control Tools 232</p>
<p>12.7 The power of PLS and PCA 233</p>
<p>12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240</p>
<p>12.9 Challenges for Implementation of PAT Tools 244</p>
<p>12.10 Future PAT Tools 247</p>
<p>13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255<br /> Duncan Low and Joseph Phillips</p>
<p>13.1 Introduction 255</p>
<p>13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256</p>
<p>13.3 Process Analytical Technology (PAT) 261</p>
<p>13.4 Quality by Design 263</p>
<p>13.5 Implementing QbD and PAT 266</p>
<p>13.6 Conclusions 282</p>
<p>Acknowledgments 283</p>
<p>References 283</p>
<p>Index 287</p>
<p>Preface xv</p>
<p>Preface to the Wiley Series on Biotechnology and Related Topics xvii</p>
<p>Contributors xix</p>
<p>1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1<br /> Rohin Mhatre and Anurag S. Rathore</p>
<p>1.1 Introduction 1</p>
<p>1.2 Critical Quality Attributes 2</p>
<p>1.3 An Overview of Design Space 3</p>
<p>1.4 Raw Materials and their Impact on QbD 4</p>
<p>1.5 Process Analytical Technology 4</p>
<p>1.6 The Utility of Design Space and QbD 5</p>
<p>1.7 Conclusions 7</p>
<p>2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9<br /> Steven Kozlowski and Patrick Swann</p>
<p>2.1 Introduction 9</p>
<p>2.2 Quality by Design 10</p>
<p>2.3 Relevant Product Attributes 11</p>
<p>2.4 Manufacturing Process 14</p>
<p>2.5 Developing a Design Space 18</p>
<p>2.6 Uncertainty and Complexity 22</p>
<p>2.7 Future Horizons 23</p>
<p>2.8 QbD Submission Thoughts 25</p>
<p>2.9 Implementation Plans 26</p>
<p>2.10 Summary 27</p>
<p>3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31<br /> David L. Narum</p>
<p>3.1 Introduction 31</p>
<p>3.2 The Malaria Genome and Proteome 34</p>
<p>3.3 Expression of Two Malaria Antigens in P. pastoris 34</p>
<p>3.4 Summary 46</p>
<p>4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53<br /> Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman</p>
<p>4.1 Introduction 53</p>
<p>4.2 Examples of Criticality Determination 60</p>
<p>4.3 Conclusion 81</p>
<p>5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85<br /> Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore</p>
<p>5.1 Introduction 85</p>
<p>5.2 Approach Toward Process Characterization 87</p>
<p>5.3 Risk Analysis 88</p>
<p>5.4 Small–Scale Model Development and Qualification 89</p>
<p>5.5 Design of Experiment Studies 94</p>
<p>5.6 Worst Case Studies 96</p>
<p>5.7 Definition of Design Space 99</p>
<p>5.8 Definition of Validation Acceptance Limits 103</p>
<p>5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106</p>
<p>6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111<br /> Peter K. Watler and John Rozembersky</p>
<p>6.1 Introduction 111</p>
<p>6.2 Applications of TFF in Biotechnology 113</p>
<p>6.3 Tangential Flow Filtration Operating Principles 113</p>
<p>6.4 TFF Design Objectives 115</p>
<p>6.5 Membrane Selection 115</p>
<p>6.6 TFF Operating Parameter Design 118</p>
<p>6.7 TFF Diafiltration Operating Mode Design 122</p>
<p>6.8 Summary 125</p>
<p>7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127<br /> Douglas J. Cecchini</p>
<p>7.1 Introduction 127</p>
<p>7.2 Establishing Design Space for Purification Processes during Process Development 128</p>
<p>7.3 Applications of Design Space 131</p>
<p>7.4 Cell Harvest and Product Capture Steps 131</p>
<p>7.5 Protein A Capture Column 136</p>
<p>7.6 Hydrophobic Interaction Chromatography 137</p>
<p>7.7 Anion Exchange Chromatography 138</p>
<p>7.8 Summary 141</p>
<p>8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143<br /> Gail Sofer and Jeffrey Carter</p>
<p>8.1 Introduction 143</p>
<p>8.2 Current and Future Approaches to Virus Clearance Characterization 143</p>
<p>8.3 Benefits of Applying Design Space Principles to Virus Clearance 144</p>
<p>8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145</p>
<p>8.5 Developing a Virus Clearance Design Space 148</p>
<p>8.6 Staying in the Design Space 156</p>
<p>8.7 Conclusion 157</p>
<p>9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161<br /> Kingman Ng and Natarajan Rajagopalan</p>
<p>9.1 Introduction 161</p>
<p>9.2 Quality by Design (QbD) Approach 162</p>
<p>9.3 Target Product Profile (TPP) 163</p>
<p>9.4 Molecular Degradation Characterization 164</p>
<p>9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166</p>
<p>9.6 Preformulation Characterization 167</p>
<p>9.7 Initial Formulation Risk Assessments 168</p>
<p>9.8 Formulation Optimization and Design Space 169</p>
<p>9.9 Selection of Solution Formulation Composition 171</p>
<p>9.10 Summary 173</p>
<p>10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175<br /> Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee</p>
<p>10.1 Introduction: QbD in Biologics Product Development 175</p>
<p>10.2 Risk Assessment Process 177</p>
<p>10.3 Examples 178</p>
<p>10.4 Conclusions 191</p>
<p>11 QbD FOR RAW MATERIALS 193<br /> Maureen Lanan</p>
<p>11.1 Introduction 193</p>
<p>11.2 Background 194</p>
<p>11.3 Current Practice for Raw Materials 195</p>
<p>11.4 QbD in Development 195</p>
<p>11.5 QbD in manufacturing 196</p>
<p>11.6 QbD for organizations 197</p>
<p>11.7 Tests Available 197</p>
<p>11.8 Conclusions and Future Prospects 207</p>
<p>12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211<br /> Michael Molony and Cenk Undey</p>
<p>12.1 Introduction 211</p>
<p>12.2 Cell Culture and Fermentation PAT Tools 214</p>
<p>12.3 Purification PAT Tools 223</p>
<p>12.4 Formulation PAT Tools 228</p>
<p>12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230</p>
<p>12.6 Chemometrics and Advanced Process Control Tools 232</p>
<p>12.7 The power of PLS and PCA 233</p>
<p>12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240</p>
<p>12.9 Challenges for Implementation of PAT Tools 244</p>
<p>12.10 Future PAT Tools 247</p>
<p>13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255<br /> Duncan Low and Joseph Phillips</p>
<p>13.1 Introduction 255</p>
<p>13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256</p>
<p>13.3 Process Analytical Technology (PAT) 261</p>
<p>13.4 Quality by Design 263</p>
<p>13.5 Implementing QbD and PAT 266</p>
<p>13.6 Conclusions 282</p>
<p>Acknowledgments 283</p>
<p>References 283</p>
<p>Index 287</p>